Business UpdateMay 7, 2026, 08:08 AM
Silo Pharma to develop ibogaine for TBI; files patent
AI Summary
Silo Pharma announced a strategic initiative to develop ibogaine-based therapeutics for traumatic brain injury (TBI) and related neuropsychiatric conditions, filing a provisional patent application for its use. This move aligns with federal efforts to accelerate mental health innovation using psychedelic medicines, noting ibogaine's potential for conditions persisting after standard therapies. The company aims to address a significant unmet medical need in the TBI therapeutics market, estimated to reach $6.0 billion by 2032, as no FDA-approved treatments currently address structural or regenerative aspects of TBI.
Key Highlights
- Silo Pharma initiated a strategic initiative to develop ibogaine-based therapeutics for traumatic brain injury (TBI).
- The company filed a provisional patent application for ibogaine use in TBI, PTSD, and associated conditions.
- This initiative aligns with federal actions to accelerate mental health innovation using psychedelic medicines.
- The global TBI therapeutics market is estimated to reach $6.0 billion by 2032.
- The TBI market is projected to grow at a CAGR of 6.0% between 2025 and 2032.
- Currently, no FDA-approved therapies address structural or regenerative aspects of traumatic brain injury.
Price Impact
More from SILO